

# TABLE OF CONTENTS

<b>Cardiology I</b> .....	1
Faculty Panel .....	3

## Blood Pressure Management

*By Karen J. McConnell, Pharm.D., FCCP, BCPS-AQ Cardiology;  
and William L. Baker, Pharm.D., FCCP, FACC, BCPS, AQ-Cardiology*

Epidemiology .....	7
HTN Guidelines .....	8
Uncomplicated HTN .....	10
HTN with Concomitant Disease States .....	12
Resistant HTN .....	16
Ambulatory and Home Blood Pressure Monitoring .....	19
Hypertensive Urgency and Emergency .....	20
Hypotension .....	22
HTN and Pharmacogenomics .....	23
Conclusion .....	23
References .....	24

## Dyslipidemia

*By Laura H. Waite, Pharm.D., BCPS, CLS, BC-ADM;  
and Yvonne L. Phan, Pharm.D., BCPS*

Introduction .....	33
Historical Approach to Dyslipidemia Treatment .....	34
New Dyslipidemia Management Guidelines .....	36
Comparison of Previous and Current Dyslipidemia Treatment Approaches .....	39
Cardiovascular Risk Assessment .....	39
Traditional and Nontraditional Risk Factors .....	40
Application of Recommendations to Patient Care .....	43
Nonstatin Therapies .....	46
New Evidence for Use of Nonstatin Agents .....	48
Emerging Therapies for Dyslipidemia .....	49
Conclusion .....	52
References .....	52

## Pulmonary Arterial Hypertension

*By Kristen T. Pogue, Pharm.D., BCPS, AQ-Cardiology;  
and Claire P. Walter, Pharm.D., BCPS*

Introduction .....	61
Therapeutic Options .....	63
Combination Therapy .....	70
Treatment Guidelines .....	72
Practical Considerations .....	73
Conclusion .....	76
References .....	77

<b>Cardiology II</b> .....	85
Faculty Panel .....	87

## Valvular Heart Disease

*By Douglas L. Jennings, Pharm.D., FCCP, FAHA, AACC, BCPS,  
AQ-Cardiology*

Introduction .....	91
Aortic Stenosis .....	92
Mitral Valve Disease .....	99
Antithrombotic Potpourri .....	101
Conclusion .....	104
References .....	104

## Infective Endocarditis

*By Laura A. Siemianowski, Pharm.D., BCPS, BCCCP;  
and Lucia Rosé, Pharm.D., AAHIVP*

Introduction .....	111
Diagnosis and Role of Empiric Therapy .....	112
Pharmacologic Management of Causative Organisms .....	112
Evaluation of Therapeutic Outcomes .....	121
Management of Antibiotic Allergies .....	123
Role of Outpatient Antibiotic Therapy .....	123
Antimicrobial Prophylaxis .....	123
Conclusion .....	124
References .....	125

## Oral Anticoagulants for VTE and Stroke Prevention in Atrial Fibrillation

*By Nancy L. Shapiro, Pharm.D., FCCP, BCPS;  
and Shubha Bhat, Pharm.D., BCACP*

Introduction .....	135
Anticoagulant Pharmacology .....	135
Treatment of VTE .....	136
Stroke Prevention in Atrial Fibrillation .....	141
Treatment Controversies .....	144
Conclusion .....	149
References .....	151